Reverse fatty liver with these 2 common drugs offering a safe, fast solution for MASLD

Scientists in Barcelona may have uncovered a groundbreaking approach to treating metabolic liver conditions using two widely available medicines. The study focuses on drug repurposing, a strategy that leverages existing medications for new therapeutic purposes, potentially accelerating treatment availability. Researchers found that pemafibrate, commonly used to manage cholesterol, and telmisartan, a blood pressure medication, could work together to reduce liver fat and prevent complications linked to metabolic dysfunction-associated steatotic liver disease (MASLD). Preclinical studies in rats and zebrafish demonstrated that the combination not only lowered liver fat but also improved cholesterol and blood pressure levels. While human trials are still needed, this research highlights the